Ascentage Pharma soars on deal with cancer drug competitor
The Chinese drug developer put a rocket booster under its share price after enlisting a Japanese rival as a new equity partner and unveiling plans for a U.S. listing Key…
6855.HK
Recent Articles
RELATED ARTICLES
Discover hidden China stock gems in our weekly newsletter